WallStreetZenWallStreetZen

NASDAQ: BNTX
Biontech Se Stock

$91.43-1.36 (-1.47%)
Updated Feb 28, 2024
BNTX Price
$91.43
Fair Value Price
N/A
Market Cap
$21.73B
52 Week Low
$88.00
52 Week High
$136.92
P/E
7.67x
P/B
1.04x
P/S
3.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.97B
Earnings
$2.93B
Gross Margin
90.9%
Operating Margin
58.73%
Profit Margin
41.6%
Debt to Equity
0.12
Operating Cash Flow
$6B
Beta
0.84
Next Earnings
Mar 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BNTX Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BNTX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BNTX is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BNTX is good value based on its earnings relative to its share price (7.67x), compared to the US market average (35.52x)
P/E vs Market Valuation
BNTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BNTX due diligence checks available for Premium users.

Be the first to know about important BNTX news, forecast changes, insider trades & much more!

BNTX News

Valuation

BNTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
7.67x
Industry
13.96x
Market
35.52x
BNTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BNTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

BNTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.04x
Industry
6.14x
BNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BNTX's financial health

Profit margin

Revenue
$952.4M
Net Income
$170.9M
Profit Margin
17.9%
BNTX's Earnings (EBIT) of $4.09B... subscribe to Premium to read more.
Interest Coverage Financials
BNTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$23.6B
Liabilities
$2.5B
Debt to equity
0.12
BNTX's short-term assets ($19.74B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNTX's short-term assets ($19.74B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$863.0M
Investing
-$1.3B
Financing
-$330.9M
BNTX's operating cash flow ($5.63B)... subscribe to Premium to read more.
Debt Coverage Financials

BNTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BNTX$21.73B-1.47%7.67x1.04x
ARGX$22.25B-3.28%-49.85x6.93x
ALNY$19.55B-2.37%-44.10x-88.61x
BGNE$18.68B-0.67%-274.58x5.28x
RPRX$18.29B-2.20%12.05x1.81x

Biontech Se Stock FAQ

What is Biontech Se's quote symbol?

(NASDAQ: BNTX) Biontech Se trades on the NASDAQ under the ticker symbol BNTX. Biontech Se stock quotes can also be displayed as NASDAQ: BNTX.

If you're new to stock investing, here's how to buy Biontech Se stock.

What is the 52 week high and low for Biontech Se (NASDAQ: BNTX)?

(NASDAQ: BNTX) Biontech Se's 52-week high was $136.92, and its 52-week low was $88.00. It is currently -33.22% from its 52-week high and 3.9% from its 52-week low.

How much is Biontech Se stock worth today?

(NASDAQ: BNTX) Biontech Se currently has 237,715,500 outstanding shares. With Biontech Se stock trading at $91.43 per share, the total value of Biontech Se stock (market capitalization) is $21.73B.

Biontech Se stock was originally listed at a price of $14.24 in Oct 10, 2019. If you had invested in Biontech Se stock at $14.24, your return over the last 4 years would have been 542.06%, for an annualized return of 59.18% (not including any dividends or dividend reinvestments).

How much is Biontech Se's stock price per share?

(NASDAQ: BNTX) Biontech Se stock price per share is $91.43 today (as of Feb 28, 2024).

What is Biontech Se's Market Cap?

(NASDAQ: BNTX) Biontech Se's market cap is $21.73B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biontech Se's market cap is calculated by multiplying BNTX's current stock price of $91.43 by BNTX's total outstanding shares of 237,715,500.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.